Drugs > Azacitidine News
You are currently reading Azacitidine news, below you will find the latest Azacitidine news available at Drug Topics. For more general Azacitidine information please visit Azacitidine. Azacitidine is categorized in the A index of drugs (by medical name) and in V index of drugs (by common name).
We have no matching items at this time. Please check back shortly. |
EU Grants VIDAZA® Full Marketing Authorization For The Treatment Of Patients With Higher-Risk Myelodysplastic ... (Medical News Today) Celgene International SĂ rl (Nasdaq:CELG) today announced that its cancer drug, VIDAZA (azacitidine), has been granted full marketing authorization by the European Commission for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: -- Intermediate- Celgene's azacitidine receives European marketing approval (PharmaBiz) Copyright © Saffron Media Pvt. Ltd. Designed & Maintained by Fast Cursor UPI NewsTrack Health and Science News (UPI) NASA: Ionosphere not where it should be ? Drug helps acute myeloid leukemia patients ? Semantic technology shopping is created ? Obesity increases gasoline consumption ... Health/Science news from UPI. VIDAZA (azacitidine) study reports survival benefit in higher-risk MDS extends to AML patients (News-Medical-Net) Celgene International Sŕrl (NASDAQ: CELG) today announced results from a subset analysis of the international phase III trial (AZA-001) demonstrating that the overall survival benefit observed in higher-risk MDS patients extended to patients with acute myeloid leukemia (AML). Study Of Revlimid And Vidaza In Higher-Risk MDS Is Well-Tolerated And Has High Activity (Medical News Today) Celgene International Sarl (NASDAQ: CELG) reported that results of a Phase I study combining REVLIMID and VIDAZA in patients with higher-risk myelodysplastic syndromes (MDS) found that the combination of these two therapies is well tolerated and has high activity. The data were reported during the 50th Annual Meeting of the American Society of Hematology. Data Presented At This Year's ASH Meeting Demonstrate Prolonged Overall Survival For Patients With Acute Myeloid ... (Medical News Today) The Myelodysplastic Syndromes (MDS) Foundation announced today that data presented at this year's American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens (CCR). ASH Presentation Of A Phase I Study Of REVLIMID(R) And VIDAZA(R) In Higher-Risk MDS Reports Combination Is ... (Medical News Today) Celgene International SĂ rl (NASDAQ: CELG) reported that results of a Phase I study presented today combining REVLIMID and VIDAZA in patients with higher-risk myelodysplastic syndromes (MDS) found that the combination of these two therapies is well tolerated and has high activity. The data were reported during the 50th Annual Meeting of the American Society of Hematology. Prolonged Overall Survival For Patients With Acute Myeloid Leukemia Demonstrated By Data (Medical News Today) The Myelodysplastic Syndromes (MDS) Foundation have announced that data presented at this year's American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens (CCR). ASH Presentation Shows Continued Treatment With Azacitidine Improves Responses In Patients With Higher-Risk ... (Medical News Today) Celgene UK today reports that an analysis presented today of a phase III international clinical trial (AZA-001) of higher-risk patients with myelodysplastic syndromes (MDS), demonstrated that continued treatment with azacitidine can improve patient responses. The data were presented at the 50th Annual American Society of Hematology meeting in San Francisco, CA. VIDAZA(R) AZA-001 Study Reports Unprecedented Survival Benefit In Higher-Risk MDS Extends To AML Patients (Medical News Today) Celgene International SĂ rl (NASDAQ: CELG) today announced results from a subset analysis of the international phase III trial (AZA-001) demonstrating that the overall survival benefit observed in higher-risk MDS patients extends to patients with acute myeloid leukemia (AML). |
Zacks Analyst Blog Highlights: Celgene Corp., Cytori Therapeutics,... Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Zacks Bull and Bear of the Day Highlights: Celgene Corp., Marriott... Zacks Equity Research highlights Celgene Corporation as the Bull of the Day and Marriott International as the Bear of the Day. Celgene's Healthy Outlook The acquisition of Pharmion brings three medically meaningful products -- Thalomid, Revlimid and Vidaza -- into market, which will drive growth in 2009 and beyond. EU Grants VIDAZA Full Marketing Authorization For The Treatment ... Main Category: Lymphoma / Leukemia Also Included In: Blood / Hematology ; Cancer / Oncology ; Regulatory Affairs / Drug Approvals Article Date: 30 Dec 2008 - 1:00 PST Celgene International Sarl today announced ... EU Grants VIDAZA Full Marketing Authorization For The Treatment Of... Celgene International Sarl today announced that its cancer drug, VIDAZA , has been granted full marketing authorization by the European Commission for the treatment of adult patients who are not eligible for ... 5 Stocks Ready for Liftoff Are you really a growth investor? It's worth asking. Fast-moving tech stocks have taken a beating recently, leading to a slew of bargains for those with the guts to buy. To The Point Credit card giant American Express and commercial financial firm CIT Group won preliminary approval to receive $3.39 bil and $2.33 bil, respectively, from the Treasury's $700 bil financial rescue program. European Commission Grants Vidaza Full Marketing Authorization for... European Commission Grants Vidaza Full Marketing Authorization for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes And Acute Myeloid Leukaemia BOUDRY, Switzerland-- --Dec 23, 2008 - Celgene ... Continue reading "Celgene gets European approval for blood-cancer drug Vidaza" Biotechnology company Celgene today said that European regulators approved its drug Vidaza for use by patients with high-risk forms of bone marrow and blood cell cancers. NewsTrack Health and Science News The U.S. space agency says it has discovered the boundary between the Earth's upper atmosphere and space has moved to extraordinarily low altitudes. |
Drug Topics
Timely and Factual Drug Information and News
Drug Index
If you are researching a particular drug and know its common name use the alphabetical links below to quickly navigate to your desired subject.
If you are researching a particular drug and know its medical name use the alphabetical links below to quickly navigate to your desired subject.
Recommended Drug Sites
The following drug sites are listed in alphabetical order.
Recommended Health Sites
The following health sites are listed in alphabetical order.
- Anti-Aging Revolution
- Hormone Health
- Medaus Compounding Center
- Personal Trainer Search
- Womens Health Concerns
Bookmark Us
The On Topic Network
This website is part of The On Topic Network.
Thank You
Drug-Topics.org was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.